Alkermes plc (ALKS) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 29 analysts4.6% Above Target
ALKS trades 4.6% above Wall Street's consensus target of $52.60.
Current Price$55.14
Average Target$52.60
Target
Current
Low$43.00
Median$54.00
High$65.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-141.6%
(Declining)
Analyst Spread41.8%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes ALKS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
ALKS Price Target Analysis
Updated July 7, 2026As of July 7, 2026, Alkermes plc (ALKS) has a Wall Street consensus price target of $52.60, based on estimates from 29 covering analysts. With the stock currently trading at $55.14, this represents a potential downside of -4.6%. The company has a market capitalization of $9.19B.
Analyst price targets range from a low of $43.00 to a high of $65.00, representing a 42% spread in expectations. The median target of $54.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 3 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ALKS trades at a trailing P/E of 38.6x. Analysts expect EPS to grow -141.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $42.56, with bear and bull scenarios of $26.81 and $56.08 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+38.4%
Industry Consensus
Avg Forward P/E
17.3x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INVAInnoviva, Inc. | $1.6B | $21.82 | $37.00 | +69.6% | Buy | 6.1x | 10 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.7B | $47.41 | $65.00 | +37.1% | Buy | 19.1x | 14 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.77 | $34.38 | +33.4% | Buy | 67.7x | 37 |
 AXSMAxsome Therapeutics, Inc. | $12.5B | $242.60 | $262.38 | +8.2% | Buy | — | 26 |
 INTRInter & Co, Inc. | $2.5B | $5.69 | $9.40 | +65.2% | Buy | 1.4x | 6 |
 JAZZJazz Pharmaceuticals plc | $15.3B | $244.17 | $257.44 | +5.4% | Buy | 9.6x | 48 |
 TEVATeva Pharmaceutical Industries Limited | $38.9B | $33.44 | $40.00 | +19.6% | Buy | 15.9x | 46 |
 BHCBausch Health Companies Inc. | $1.8B | $4.81 | $8.00 | +66.3% | Buy | 1.1x | 38 |
 COLLCollegium Pharmaceutical, Inc. | $1.2B | $37.47 | $58.00 | +54.8% | Buy | 4.8x | 12 |
 AVPTAvePoint, Inc. | $2.6B | $12.04 | $15.00 | +24.5% | Buy | 29.8x | 12 |
ALKS — Frequently Asked Questions
Quick answers to the most common questions about buying ALKS stock.
What is the ALKS stock price target for 2026?
Wall Street's consensus price target for ALKS is $52.6, -4.6% from its current price of $55.14. The below-market target from 29 analysts suggests limited near-term appreciation.
Is ALKS a buy, sell, or hold?
ALKS has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $52.6 implies -4.6% downside from current levels.
Is ALKS stock overvalued or undervalued?
ALKS's current price is $55.14 with a consensus target of $52.6 (-4.6% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can ALKS stock go?
The most bullish Wall Street analyst has a price target of $65 for ALKS, while the most conservative target is $43. The consensus of $52.6 represents the median expectation. Our quantitative valuation model projects a bull case target of $56 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover ALKS stock?
ALKS is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 10 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ALKS stock forecast?
The 12-month ALKS stock forecast based on 29 Wall Street analysts shows a consensus price target of $52.6, with estimates ranging from $43 (bear case) to $65 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $43, with bear/bull scenarios of $27/$56.
What is ALKS's fair value based on fundamentals?
Our quantitative valuation model calculates ALKS's fair value at $43 (base case), with a bear case of $27 and bull case of $56. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
Should I buy ALKS stock?
Analysts are cautious on ALKS, with 3 Sell ratings and a price target of $52.6 (-4.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ALKS price targets vary so much?
ALKS analyst price targets range from $43 to $65, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $52.6 consensus represents the middle ground. Our model's $27-$56 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare